Printed by Michael Blake on 9/8/2015 10:44:56 AM. For personal use only. Not approved for distribution. The NCCN Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved.

NCCN Disease Indication	Agent	Brand Name(s)	Pharmacologic Class	Route(s)	ICD-10 Code	ICD-9 Code	NCCN Recommended Use	NCCN Category	FDA Disease Indication
Multiple Myeloma	Bendamustine hydrochloride NCCN Chemotherapy Order Templates (Includes Evidence-based References)	Treanda®	Alkylating agent	IV	C88.8, C90.00, C90.02, C90.10, C90.12, C90.20, C90.22, C90.30, C90.32, D47.Z9, Z85.79	203.00, 203.02, 203.10, 203.12, 203.80, 203.82, 238.6, V10.79	Therapy for previously treated myeloma on or off clinical trials for disease relapse or for progressive or refractory disease • as a single agent • in combination with lenalidomide and dexamethasone	2A	**Chronic Lymphocytic Leukemia:** Bendamustine hydrochloride for injection is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first-line therapies other than chlorambucil has not been established. **Non-Hodgkin's Lymphoma:** Bendamustine hydrochloride for injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Multiple Myeloma	Bortezomib NCCN Chemotherapy Order Templates (Includes Evidence-based References)	Velcade®	26S Proteasome inhibitor	IV, SC	C88.8, C90.00, C90.10, C90.20, C90.30, D47.Z9	203.00, 203.10, 203.80, 238.6	Primary chemotherapy for progressive solitary plasmacytoma or smoldering myeloma (asymptomatic) that has progressed to active (symptomatic) myeloma in • combination with dexamethasone with or without cyclophosphamide, doxorubicin, lenalidomide, or thalidomide for transplant candidates (all preferred regimens) • combination with dexamethasone with or without cyclophosphamide or lenalidomide or in MPB (melphalan, prednisone, and bortezomib) regimen for nontransplant candidates (all preferred regimens)	1; 2A for combination with dexamethasone in nontransplant candidates and for combination with dexamethasone and cyclophosphamide or lenalidomide	Bortezomib for injection is indicated for the treatment of patients with multiple myeloma. Bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma.
Multiple Myeloma	Bortezomib NCCN Chemotherapy Order Templates (Includes Evidence-based References)	Velcade®	26S Proteasome inhibitor	IV, SC	C88.8, C90.00, C90.01, C90.10, C90.20, C90.21, C90.30, C90.31, D47.Z9	203.00, 203.01, 203.10, 203.80, 203.81, 238.6	Maintenance therapy as a single agent (preferred) or in combination with prednisone or thalidomide • for active (symptomatic) myeloma responding to primary myeloma therapy • for stable or responsive disease following stem cell transplant • with second tandem transplant for stable or responsive disease following autologous stem cell transplant	2A; 2B for combination with prednisone or thalidomide	Bortezomib for injection is indicated for the treatment of patients with multiple myeloma. Bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma.
Multiple Myeloma	Bortezomib NCCN Chemotherapy Order Templates (Includes Evidence-based References)	Velcade®	26S Proteasome inhibitor	IV, SC	C88.8, C90.00, C90.02, C90.10, C90.12, C90.20, C90.22, C90.30, C90.32, D47.Z9, Z85.79	203.00, 203.02, 203.10, 203.12, 203.80, 203.82, 238.6, V10.79	Therapy on or off clinical trials for disease relapse after 6 months following primary chemotherapy with the same regimen in • combination with dexamethasone with or without cyclophosphamide, doxorubicin, lenalidomide, or thalidomide for transplant candidates • combination with dexamethasone with or without cyclophosphamide or lenalidomide or in MPB (melphalan, prednisone, and bortezomib) regimen for nontransplant candidates	1; 2A for combination with dexamethasone in nontransplant candidates and for combination with dexamethasone and cyclophosphamide or lenalidomide	Bortezomib for injection is indicated for the treatment of patients with multiple myeloma. Bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma.
Multiple Myeloma	Bortezomib NCCN Chemotherapy Order Templates (Includes Evidence-based References)	Velcade®	26S Proteasome inhibitor	IV, SC	C88.8, C90.00, C90.02, C90.10, C90.12, C90.20, C90.22, C90.30, C90.32, D47.Z9, Z85.79	203.00, 203.02, 203.10, 203.12, 203.80, 203.82, 238.6, V10.79	Therapy for previously treated myeloma on or off clinical trials for disease relapse or for progressive or refractory disease • as a single agent (preferred) • in combination with dexamethasone with or	1 as a single agent, in combination with panobinostat and dexamethasone, and in combination	Bortezomib for injection is indicated for the treatment of patients with multiple myeloma. Bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma.

The NCCN Drugs & Biologics Compendium (NCCN Compendium®) is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. ©2015. Multiple Myeloma V.1.2016. 09/04/2015 The NCCN Compendium® and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
The NCCN Compendium neither represents an all-inclusive listing of every drug and biologic used in cancer treatment nor every oncology-related use and indication for drugs and biologics. Any clinician seeking to apply or consult the NCCN Compendium is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.